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Abstract Circulating connective tissue components including the aminoterminal propeptides of type III collagen
(PIIINP), type I collagen (PINP) and hyaluronan were determined in patients hospitalised for pneumonia of suspected
bacterial origin.Ninety patients were included, 64 of these were followed prospectively for up to 21days after initiation
oftherapy.SerumPIIINPwasdeterminedbyRIA, s-PINP by ELISA, ands-hyaluronanbyaradiometric assay.S-PIIINProse
significantly above the zero value within 24 h in both pneumococcal pneumonia (T0: 5.3 mg/l, 95% CI: 2.7^8.1 mg/l vs.T1:
6.7 mg/l,95% CI: 3.8^9.1, Po0.01) and in pneumonia of unknown aetiology (T0: 4.0 mg/l,95% CI: 3.6^4.8 vs.T1: 4.5 mg/l,95%
CI: 3.8^5.1, Po0.05) followedbya gradual decline.At T1,S-PIIINP washigher inpneumococcalpneumonia comparedwith
pneumonia of unknown aetiology (Po0.05). By contrast, s-PINP tended to decline within 24 h in both pneumococcal
pneumonia (T1: 30 mg/l,95%CI:23^40, ns) andinpneumoniaofunknownaetiology (T1:32 mg/l,95%CI:22^42, ns) followed
bya steadyincrease.The PINPantigensizedistributionremainedconstantthroughoutthe follow-upperiod.S-hyaluronan
in pneumococcal pneumonia paralleled s-PIIINP reaching a peak value on day1 (121 mg/l, 95% CI: 65^191, P=0.38).There
was a positive correlation between s-PIIINP and C-reactive protein (CRP).The study demonstrates, that community-
acquired pneumonia elicits a differentiatedmesenchymalresponse, which is turned down in response to successful anti-
biotic therapy.r2003 Publishedby Elsevier Science Ltd.
doi:10.1053/rmed.2003.1497, available online athttp://www.sciencedirect.com
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Bacterial pneumonia is a leading cause of hospitalisation
with a mortality ranging from 4% to 36 % (1,2). The as-
sessment of in£ammatory activity and prognosis relies
on clinical ¢ndings combinedwith the extent of pulmon-
ary opacities on X-ray and acute phase reactants (1,3).
However, acute phase proteins are only indirectly
coupled to the in£ammatory process, because they are
synthesised at sites topographically separated from the
in£ammatory focus (4). This implies, that they may not
provide an optimal re£ection of in£ammatory activity
as reported in e.g. systemic lupus erythematosus (5).
From a pathophysiological point of view, biomarkers,$This study was supportedby grants from:The Institute of Clinical
Research,Odense University,The Danish Medical Research Council,
IngemannO.Bucks Foundation and The Hjbjerg Foundation.
Received 25 June 2002, accepted in revised form 4 November 2002
*Correspondence should be addressed to: Claudia NordenbDkMD,
Department of Internal Medicine, Section of Rheumatology,Odense
University Hospital, 29 Sdr.Boulevard,DK-5000 Odense C,Denmark.
Fax: +45-65-91-62-21
E-mail address: claudia@dadlnet.dkwhich are directly related to the in£ammatory process,
would appear to possess inherent advantages. Extracel-
lular matrix proteins are abundant in lung tissue with
collagen accounting for approximately 20% of the dry
weight (6).Besides its sca¡oldingrole, the connective tis-
sue serves both as a site and a target for in£ammatory
cells and mediators of in£ammation in infectious and
non-infectious lung in£ammation. In a broad spectrum
of ¢broproliferative conditions and bone diseases, the
serum concentration of procollagen peptides, which are
cleaved o¡ in a stoichiometric manner following secre-
tion of procollagen into the extracellular space, has been
shown to bereliable indicators of thebiosynthetic rate of
their parent collagen types, collagen I and III in particular
(7^13). This also applies to hyaluronan in serum (14^16).
Studies in chronic ¢brosing lung diseases have yielded
con£ictingresults (17^19). In oneprevious cross-sectional
study of pneumonia, s-PIIINP was increased (20). The
purposes of thepresentprospective study were (1) to in-
vestigate if pneumonia of suspected bacterial origin eli-
cits a mesenchymal response detectable as changes in
the serum concentration of the aminoterminal propep-
tides of collagen III (PIIINP), I (PINP) and hyaluronan and
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conventionalmarkers of in£ammation.
METHODS
Patients and study design
The study comprised 90 patientswith acute community-
acquired pneumonia. A total of 90 patients were in-
cluded,45men and 45women, aged 20^95 years.Thepa-
tients ful¢lled the following criteria: A history of cough
or sputum production or pleuritic chest pain or dys-
pnoea, rectal temperature above 37.91C, chest X-ray
showing in¢ltrative lung changes, a totalwhite blood cell
(WBC) count above10.0109/l (normalrange: 4.0109^
10.0109/l) and/or serum C-reactive protein (CRP) ex-
ceeding 40mg/l (normal range:o10mg/l). Patients trea-
ted with oral or intravenous glucocorticoids within 2
weeks before hospitalisation were excluded as were pa-
tients with malignancies, chronic renal and hepatic dis-
ease, other ¢broproliferative diseases, abnormalities of
growth and development, major surgery within 3
months, pregnancy and inability to give informed con-
sent. Twenty patients with mild asthma or mild chronic
obstructive lung disease were included. Blood cultures,
sputum culture and chest X-ray was done on all patients
and when considered during the course. Blood samples
were taken from all patients on admission (day 0).
Among the follow-up cohort, the duration of symp-
toms before admission averaged 3.5 days (0.5^7 days).
The mean temperature on admission was 39.01C (range
37.4*^41.31C). Fifty-three (83%) had positive stetho-
scopic ¢ndings. The lag time between initiation of anti-
biotic treatment and the collection of serum samples
did not exceed12h. Serial blood samples were obtained
from 64 patients on days 1, 3, 5, 7,10, and 21. All patients
were treated with antibiotics for at least 7 days (penicil-
lin V or G: 52 patients, ampicillin/pivampicillin: nine pa-
tients, erythromycin: four patients). Fifty-three and 47
patients completed1and 3weeks follow-up,respectively.
Two patients died and 15 dropped out for various
reasons (21).
Ethics
The study was performed in accordancewith theHelsin-
ki II declaration. The local ethics committee approved
theresearchprotocol.Thepatientswere informed about
the study verbally and in writing and all gave their writ-
ten consent. They were told that they could withdraw
from the study at any time.*Including a few patients who had received antipyretics before
admission.Biochemical analyses
Sera for quanti¢cation of connective tissue components
were stored at 801C until analysed for serum PIIINP,
PINP and serum hyaluronan. Hyaluronan was only mea-
sured consecutively in pneumococcal pneumonia.
PIIINPwas determinedby the PIIINP Radioimmunoas-
say Kit (Orion Diagnostica,Oulu, Finland) (22), which is
an equilibrium type of assay.The normal range in our la-
boratory, basedonhealthy, adultblooddonors (aged 20^
80 years), was1.9^4.5mg/l (5th and 95th percentiles, re-
spectively) with a median value of 2.9mg/l.No sex or age
di¡erences were found.The intra- and inter-assay coe⁄-
cients of variationwere 4.3% and 9.0%, respectively.
PINP wasmeasured bymeans of ELISA (13), which re-
cognises two molecular size variants of PINP antigen
shown by size chromatography and corresponding to an
apparent molecular mass of 30 and 100kDa. These size
variants have been demonstrated to be monomeric a1-
chains of PINP and a1-chains in a trimeric structure (23).
The ELISA system uses immunospeci¢cally puri¢ed rab-
bit anti-PINP antibodies as both catcher and indicator
antibodies.The intra- and inter-assay coe⁄cient of varia-
tion was o5.0% and 5.4%, respectively. In 57 healthy,
adult subjects (age 19^77 years, 19 women and 38 men)
the serum concentration was 23^84mg/l (5th and 95th
percentiles, respectively) with a median value of 56mg/l.
PINP size chromatography was carried out by apply-
ing 200ml serum to a Superose12 HR10/30 column con-
nected to a fast-performance liquid chromatography
(FPLC) system (Pharmacia, Uppsala, Sweden).The chro-
matography was performed with PBS, pH 7.3 at a £ow
rate of 0.5ml/min and 0.5ml fractions were collected
(13). Serum from two selected patients was subjected to
size chromatography. One of the patients had rising s-
PINP throughout the observation period (4300% rise
fromday 0 (35mg/l) to day 21 (135mg/l)) and the other pa-
tient had a constant, normal serum level around 40mg/l
throughout the course. Samples from days 0, 5,10 and 21
were analysed in the patient with rising PINP levels and
sera from days 0 and 21 were analysed in the other pa-
tient (Fig. 4).Molecular size chromatography in a healthy
person has been reported previously (24).
Determination of hyaluronanwas performedwith the
Pharmacia HA test (Pharmacia AB, S-751 82 Uppsala,
Sweden) as previously described (25). This radiometric
assay is based on the use of a speci¢c hyaluronan-binding
protein, isolated from bovine cartilage. The normal
range in healthy blood donors was 10^97mg/l, median
28mg/l.The inter-assay coe⁄cient of variationwas 8.3%.
Serum CRP wasmeasured by turbidimetry.
Statistical analysis
The statistical analysis was donewith Statistical Package
for the Social Science (SPSSs) Software and CIA
FIG. 1. Individual serumconcentrationsof PIIINP,PINPandhya-
luronanindi¡erent subsetsofpneumonia at T0.2=S. pneumoniae
pneumonia; 3=H. in£uenzae pneumonia; 4=atypical pneumo-
nia; 5=pneumoniaofunknownaetiology; 1= allpatients.Median
values are given.Thehatched area represents thenormalrange.
662 RESPIRATORYMEDICINE(London). Results are given as median and range unless
otherwise stated. Con¢dence intervals (CI), given for
the median of a certain variable, were calculated at the
95% level. Comparison between groups was performed
by the Mann^Whitney test for unpaired di¡erences.
Temporal di¡erences within groups were tested by
means ofWilcoxonŁ smatched-pairs signedrank sum test.
Correlation analysis was based on the Spearman rho
test.P values less than 0.05 were considered to be signif-
icant.
RESULTS
A speci¢c bacterial diagnosis couldbe established in a to-
tal of 32 (36%) of the patients. Twenty-two (24%) had
pneumococcal pneumonia, which compares well with
previous reports, which however have yielded quite
varying ¢gures (26,27). Five were infected with Haemo-
philus in£uenzae (6%), onewith Klebsiella pneumoniae and
four had atypical pneumonia. In a total of 58 (64%), a bac-
terial aetiology could not be identi¢ed.Twenty of the pa-
tients (22%) had received antibiotics before admission,
but s-PIIINP, s-PINP, s-hyaluronan,CRP and granulocyte
counts did not di¡er between treated and untreated pa-
tients. In a preliminary study of10 patients with bacterial
pneumonia, s-PIIINP did not exhibit signi¢cant changes
within the ¢rst 12h after initiation of antibiotic treat-
ment (personal observation).
Figure1illustrates the individual serumconcentrations
of s-PIIINP, s-PINP and s-hyaluronan in di¡erent subsets
of pneumonia on admission (T0). At T0, median s-PIIINP
for thewhole group (4.5mg/l,95%CI: 3.8^4.9mg/l) equal-
led the upper normal limit butwith a considerable varia-
tion between individuals. Looking at the groups
according to aetiology, PIIINP was initially slightly ele-
vated in pneumococcal pneumonia (5.1mg/l, 95% CI: 2.7^
6.3) and atypical pneumonia butwithin the normal range
inpneumonia of unknown aetiology (4.0mg/l,95%CI: 3.7^
4.7) and H. in£uenzae infection. Figure 2 illustrates the
temporal changes in s-PIIINP, s-PINP and s-hyaluronan
inpatientswithpneumonia causedby Streptococcus pneu-
moniae and Fig. 3 shows the courses of s-PIIINP and s-
PINP in pneumonia of unknown aetiology. Both ¢gures
illustrate serumvalues during treatmentwith antibiotics
and at follow-up on day 21. In both groups, s-PIIINP rose
signi¢cantly above zero level within 24h after admission
reaching peak values at 6.7mg/l (95% CI: 3.8^9.1, Po0.01)
and 4.5mg/l (95% CI: 3.8^5.1, Po0.05), respectively. The
peak valuewas signi¢cantlyhigher in S. pneumoniaepneu-
monia as compared with pneumonia of unknown aetiol-
ogy (Po0.05). During treatment with antibiotics, s-
PIIINP declined signi¢cantly (Po0.05) in patients with S.
pneumoniae pneumonia, reaching the normal range by
day 5.Throughout the course, median s-PIIINP remained
within normalrange in pneumonia of unknown aetiology.On day 21, 10 of the patients (22%) still had elevated s-
PIIINP, ¢ve of which had pneumococcal pneumonia, four
pneumonia of unknown aetiology and one atypical pneu-
monia.
S-PINP at inclusion averaged 37mg/l (95% CI: 32^
42mg/l). Median initial s-PINP was 35mg/l (95% CI: 28^
44) in patients with S. pneumoniae pneumonia and
40mg/l (95% CI: 36^48) in patients with pneumonia of
unknown aetiology (Fig.1). In contrast to s-PIIINP, s-PINP
showed a slight decline within the ¢rst 24h of admission
in patients with pneumococcal pneumonia (T0: 31mg/l,
95% CI: 26^37 vs.T1: 30mg/l, 95% CI: 23^40, ns) and the
follow-up patients with pneumonia of unknown aetiol-
ogy (T0: 37mg/l, 95% CI: 25^48 vs. T1: 32mg/l, 95% CI:
22^42mg/l, ns).Thirty-oneper cent of thepatientsparti-
cipating in the longitudinal study had s-PINP below the
lower limit of the reference interval at T1. S-PINP then
FIG. 3. The temporal course of serum PIIINP and PINP due to
pneumonia of unknown aetiology.Median values and 95% con¢-
dence intervals are given.Thehorizontallines representthe nor-
malrange. *Po0.05, **Po0.01bycomparisonwiththeT0 value.
FIG. 2. The temporal course of serum PIIINP,PINP andhyalur-
onan due to S. pneumoniae pneumonia.Median values and 95%
con¢dence intervals are given. The horizontal lines represent
the normal range. *Po 0.05, **Po0.01by comparison with the
T0 value.
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ceeding its upper normal limit (Figs. 2 and 3).
Size chromatography of PINP in the circulation of
the two selected patients showed that the peak of the
molecular weight fractions seen at T0,T5,T10 and T21 were
identical to the peaks seen in healthy individuals (24)
(Fig. 4).S-hyaluronan at T0 was 73mg/l (95% CI: 58^88mg/l).
Patientswithpneumococcal pneumonia had slightlyhigh-
er s-hyaluronan (92mg/l, 95% CI: 68^158) as compared
with patients with pneumonia of unknown aetiology
(69mg/l, 95% CI: 49^88, Po0.05) (Fig. 1). S-hyaluronan
was onlymeasuredconsecutively inpneumococcal pneu-
monia where it paralleled s-PIIINP reaching a peak value
on day1 (121mg/l, 95% CI: 65^191, P=0.38). Normal range
was reached between days1and 3 (Fig. 2).
Brie£y,CRP at T0 was highly elevated in all categories
of pneumonia. At day 1, patients with pneumococcal
pneumonia had higher CRP levels compared with pneu-
monia of unknown aetiology (Po0.05). After day 1, CRP
steadily declined in both groups reaching normal range
on days 21 and 10, respectively. In both groups, elevated
granulocyte counts normalisedwithin 5 days after initia-
tion of therapy.
Among the patients followed consecutively, therewas
signi¢cant correlations between s-PIIINP and conven-
tional acute phase reactants like CRP (Po0.01), while
FIG. 4. Analysis of molecular weight fractions by size chromatography of serum from a patient with rising PINP during the course
(No.1) anda patientwith a constantlynormalserumlevelduring the course (No.2).Sampleswere analysedondays 0,5,10 andday 21in
the patientwithrising PINP levels and atdays 0 and 21in the other patient.
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tered correlation was demonstrated between s-PIIINP
and s-PINP.
DISCUSSION
The present study demonstrates for the ¢rst time, that
acute pneumonia acquired outside hospital is associated
with a di¡erentiated mesenchymal response involving
collagen III in particular.The PIIINP responsewas highest
in pneumococcal pneumonia as comparedwith pneumo-
nia of unknown aetiology.
Increased s-PIIINP has been reported in one previous
cross-sectional study of pneumonia (20). The origin of
the increased s-PIIINP and s-hyaluronan cannotbe deter-
mined from the present study. Although the concentra-
tion of PIIINP in bronchial lavage (BAL) £uid from
patients with bacterial pneumonia did not exceed nor-
mal values (20), this observation should be interpreted
with caution because PIIINP may have been degraded
into smaller fragments by proteolytic enzymes in the
BAL £uid.The sequential changes of s-PIIINP and hyalur-
onan in the present study are similar to the pattern re-
ported during wound healing in experimental animals
and humans, indicating that they re£ect in£ammation
and repair in the a¡ected lung tissue (8,28^33).
The relatively small rise in s-PIIINP in pneumonia may
re£ect that the structural damage to the lung is less se-
vere as compared with ¢brosing lung diseases like acute
respiratory distress syndrome (ARDS), where signi¢cant
increases in s-PIIINP have been reported (20,34). In var-
ious ¢brosing lung diseases in which the mechanism be-
hind the recruitment and activation of ¢broblasts and
the subsequent production of extracellular matrix isunknown, there have been con£icting reports on serum
and BAL PIIINP content (17,19,35,36).
The PIIINP response was less pronounced in patients
with pneumonia of unknown origin as compared with
pneumococcal pneumonia. In this context, it should be
noted that the most severely ill patients with the most
extensive X-ray changes were found among the latter
group. This suggests that s-PIIINP is determined by the
extent of the infectious in¢ltrate rather thanby the spe-
ci¢c pathogen.This notion is favoured by animal experi-
ments demonstrating a parallelismbetween s-PIIINP and
collagenproliferation in subcutaneousgranulomas inrats
(8).Ten patients hadpersistently elevated s-PIIINPon day
21.Conceivably, this sustainedconnective tissueresponse
represents extended repair and regeneration mechan-
isms at the site of lung in£ammation.
In contrast to PIIINP and hyaluronan, the lowest s-
PINP values were recorded within the ¢rst 24h in all
kinds of pneumonia. Subsequently, s-PINP gradually in-
creasedwithin the normal reference area andhad appar-
ently not stabilisedby the end of the observation period
(Figs. 2 and 3). This observation is at variance with ex-
perience fromwoundhealing studies, where the concen-
tration of propeptides from collagens I and III are
increased in serum as well as in wound £uid (29,37,38).
Mostof the PINPpresent in serumprobablyderives from
the continuous turnover of skin and skeletal collagen
(39,40). Most likely, the decreased PINP response to
pneumonia serves to ensure that adequate energy sup-
plies are directed to the trauma area at the cost of the
household synthesis in remote and una¡ected tissues
(40). Since the duration of bed rest in this otherwise
healthy patient cohort rarely exceeded a few days, de-
creased synthesis of bone collagen due to immobilisation
probably was a contributing factor to the low PINP
CONNECTIVE TISSUERESPONSES INPNEUMONIA 665values (41) Alternatively, the proportion of the di¡erent
sizevariants of PINPcouldbe alteredin serumduring the
course of an infection. To study this issue, serum from
two selected patients was subjected to size chromato-
graphy.This analysis showed that the distribution ofPINP
size variants remained stable throughout the course of
the disease, and that the sizevariantpro¢le didnot di¡er
from healthy controls (24) (Fig. 4).
In conclusion, this study has demonstrated, that acute
bacterial pneumonia elicits a transient mesenchymal re-
action, which is gradually turned down in response to
targeted antibiotic therapy and resolution of the infec-
tious in¢ltrate. However, in uncomplicated bacterial
pneumonia the clinical utility of thesemolecules as mar-
kers of disease activity is restricted due to the modest
amplitude.
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